Partnering for an NGS panel
LOS ANGELES—Children's Hospital Los Angeles and Thermo Fisher Scientific have joined forces to develop a next-generation sequencing (NGS)-based panel designed for pediatric cancer research. The panel is a targeted DNA and RNA sequencing-based research gene panel using Thermo Fisher Scientific's Ion Torrent NGS platform and Ion AmpliSeq technology. It detects DNA mutations, gene amplifications and the expression of more than a thousand specific gene fusion variants, representing over a hundred tumor-specific gene translocations common to pediatric malignancies. This panel will include nearly all somatic genetic alterations identified for childhood cancer so far in scientific literature, and requires as little as 10ng of DNA and RNA from fixed, fresh or frozen tumor tissue.
“Targeted sequencing is showing tremendous promise as an effective and rapid solution to elucidate the molecular underpinnings of cancer,” commented Joseph Bernardo, president of Clinical Sequencing at Thermo Fisher Scientific.